Constitutive activity of the Ras/Raf/MEK/ERK1/2 signaling cascade has been reported in a wide variety of liquid and solid cancer types including AML, acute lymphoblastic leukemia (ALL), breast, melanoma and prostate cancer [11]. This evidence concerns the gene MAPK3 and acute lymphoblastic leukemia.